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Abstract 
Background 
The human OXR1 gene belongs to a class of genes with conserved functions that protect cells 
from reactive oxygen species (ROS). The gene was found using a screen of a human cDNA 
library by its ability to suppress the spontaneous mutator phenotype of an E. coli mutH nth 
strain. The function of OXR1 is unknown. The human and yeast genes are induced by 
oxidative stress and targeted to the mitochondria; the yeast gene is required for resistance to 
hydrogen peroxide. Multiple spliced isoforms are expressed in a variety of human tissues, 
including brain. 
Results 
In this report, we use a papillation assay that measures spontaneous mutagenesis of an E. coli 
mutM mutY strain, a host defective for oxidative DNA repair. Papillation frequencies with 
this strain are dependent upon a G→T transversion in the lacZ gene (a mutation known to 
occur as a result of oxidative damage) and are suppressed by in vivo expression of human 
OXR1. N-terminal, C-terminal and internal deletions of the OXR1 gene were constructed and 
tested for suppression of the mutagenic phenotype of the mutM mutY strain. We find that the 
TLDc domain, encoded by the final four exons of the OXR1 gene, is not required for 
papillation suppression in E. coli. Instead, we show that the protein segment encoded by exon 
8 of OXR1 is responsible for the suppression of oxidative damage in E. coli. 
Conclusion 
The protein segment encoded by OXR1 exon 8 plays an important role in the anti-oxidative 
function of the human OXR1 protein. This result suggests that the TLDc domain, found in 
OXR1 exons 12–16 and common in many proteins with nuclear function, has an alternate 
(undefined) role other than oxidative repair. 
Background 
Respiratory metabolism generates reactive oxygen species (ROS) that can damage many 
cellular components such as DNA, proteins and lipids [1-3]. These ROS include such 
molecules as superoxide, singlet oxygen, hydroxyl radicals, and hydrogen peroxide, which 
can be produced as by-products of aerobic metabolism, oxidoreductase enzymes and metal-
catalyzed oxidations. Hydrogen peroxide, while relatively stable, can react with Fe
2+
 via the 
Fenton reaction to produce hydroxyl radicals [4]. ROS also play a role in cell signaling, 
where they can be involved in apoptotic processes, transcriptional activation or suppression 
programs, and cell signaling cascades [5]. An increasing number of human diseases are 
associated with the damage that ROS cause, including cancer, autoimmune diseases, 
hypertension and neurodegenerative diseases [3,6-10]. Oxidative damage is also considered a 
major factor in the mechanisms of aging and age-related diseases such as Parkinson’s and 
Alzheimer’s [11-13]. 
There are two modes of action that cells can use to combat the deleterious effects of ROS on 
cellular constituents: ROS prevention and DNA repair. The first includes molecules that 
inactivate or inhibit the formation of ROS, thus preventing damage from occurring in the cell. 
Such detoxification molecules include enzymes like superoxide dismutase, catalase, and 
glutathione peroxidase [14,15], metabolites such as beta-carotene, lycopene and vitamins A, 
C and E, and minerals such as selenium and manganese [16]. These systems either prevent 
ROS from forming or scavenge them before they can cause damage to vital components of 
the cell. The second means of defense against ROS involves DNA repair enzymes that 
correct chromosomal damage caused by ROS if they are not inactivated [17]. These enzymes 
are primarily components of the base excision repair (BER) pathways in both Escherichia 
coli and higher eukaryotes, though nucleotide excision repair (NER), mismatch repair 
(MMR), and strand break repair mechanisms are also involved in repair of oxidative damage 
[18,19]. 
The 8-oxoG modified base is a frequent oxidation product of guanine that is used as a 
biomarker of oxidative DNA damage [20]. In E. coli, 8-oxoG pairs with adenine during 
replication, resulting in a G→T transversion if the lesion is not repaired. The MutM 
glycosylase (aka Fpg) functions to remove 8-oxoG from DNA, whereas the MutY protein 
removes the adenine opposite 8-oxoG, giving more time for MutM to work prior to 
replication [21]. Nth (endonuclease III) and Nei (endonuclease VIII) are two other 
glycosylases that act principally on the damaged pyrimidines [22]. E. coli mutants in most of 
these genes, either confer sensitivity to exogenous peroxide treatment, and/or display a 
spontaneous mutator phenotype as a result of their inability to repair spontaneous oxidative 
damage. Mammalian homologs of these glycosylases have also been described and are an 
area of intense study [23]. 
In a previous study using a human cDNA library to identify eukaryotic genes that either 
prevent or repair oxidative damage, the OXR1 gene was identified by its ability to suppress 
the spontaneous mutator phenotype of an E. coli nth mutH strain [24]. The OXR1 function is 
highly conserved among eukaryotes, but is not found in prokaryotes. A deletion of the OXR1 
gene in Saccharomyces cerevisiae causes an increase in sensitivity to hydrogen peroxide 
[24], and removal of a locus encoding all seven isoforms in Drosophila melanogaster results 
in lethality due to a defect in eclosion (hatching) [25]. Silencing of OXR1 mRNA by 83 % 
sensitized mosquitoes to the harmful effects of hydrogen peroxide in their drinking water. 
Interestingly, the silencing of OXR1 also resulted in decreased mRNA levels for both 
catalase and glutathione peroxidase, suggesting that (at least in insects) OXR1 may have a 
regulatory role in resistance to ROS [26]. A study examining the expression of OXR1 in the 
mouse retinal cells after exposure to high levels of oxygen showed that OXR1 expression was 
increased by 3 days exposure, when photocells were resistant to hyperoxia and remained high 
in the strain that was resistant to hyperoxia. In the sensitive strain of mice, OXR1 levels 
declined in the retina and the photocells started to degenerate [27]. Transgenic mice 
expressing the human ApoE-ε4 isoform of apolipoprotein ApoE have been characterized as 
exhibiting structural and functional abnormalities in their mitochondria [28-30]. A recent 
proteomic analysis of hippocampal cells from these mice identified OXR1 as one of the 
mitochondrial targeted gene products specifically downregulated following an ischemic insult 
[31]. By contrast, the hippocampus cells from mice transgenic for ApoE-ε3 did not show 
mitochondrial abnormalities and did not exhibit a reduction for OXR1 transcripts following 
ischemic insult. 
A recent report shows that the Bella mouse (bel), identified in a screen for mouse models of 
human movement disorders, lacks the OXR1 gene. These mice develop normally for 2 weeks 
following birth, but soon thereafter develop severe ataxia, do not show normal weight gain, 
and die within a month [32]. The pathological properties of the bel mutant mouse were 
reversed by an OXR1 transgene, confirming that loss of OXR1 was responsible for these 
neurological defects. Histological analyses of these mice show increased cell death in the 
granular cell (GC) layer of the cerebellum. These authors also report that Oxr1 is 
overexpressed in amyotrophic lateral sclerosis (ALS) patients and in mouse models of ALS, 
indicating a possible protective function of OXR1 in this neurodegenerative disorder. Both 
the human and yeast OXR1 genes are induced by heat and oxidative stress, and their proteins 
localize to the mitochondria [33]. Localization of the OXR1 protein to mitochondria is 
significant since this organelle represents a major source of ROS production in the cell. 
A bacterial papillation assay for OXR1 activity has been previously described [34,35]. It 
utilizes a strain containing the lacZ cc104 allele [36] in an E. coli mutM mutY strain [21]. In 
this background, the lacZ cc104 mutation spontaneously reverts at high frequency to wild 
type by a GC→ TA transversion (a common mutation found in DNA exposed to oxidizing 
agents). Overexpression of mutM alone completely eliminates GC→TA transversions in this 
strain, indicating they are primarily due to lesions repaired by the MutM glycosylase, 
predominantly 8 oxoG [34,35]. Thus, by growth of colonies on minimal lactose plates 
containing Xgal and IPTG, isolated colonies show high levels of Lac  +  papillae. The 
expression of OXR1 suppresses oxidative damage, which can be easily detected by a lower 
frequency of papillation in this genetic background. In this study, we use this papillation 
assay to identify which region of the OXR1 protein is important for this suppressive function. 
Surprisingly, we find that the highly conserved TLDc domain, found in the extreme C-
terminal region of most of the OXR1 isoforms, is not required for suppression of mutagenic 
activity in E. coli. Instead, the oxidation resistance function is located in a region of OXR1 
encoded by exon 8, in a segment of the gene that encodes a putative helix-turn-helix 
structural motif. 
Results 
Numbering of the OXR1 protein 
The original OXR1-producing plasmid pMV520 was identified from a library of human 
cDNAs cloned into pSE380 [24]. In this construct, the OXR1 DNA sequence starts with 
codon 200 of exon 7 (shaded lysine in Figure 1) and includes all downstream exons through 
exon 16, with the exception of exon 10. The start site for OXR1 protein expression from 
pMV520 is most likely the downstream ATG codon within exon 7 at position 225 (shaded 
methionine in Figure 1). This proposed N-terminal end for OXR1 encoded by pMV520 is 
based on the following observations. First, the OXR1 sequence in pMV520 starts with codon 
200 of exon 7 (shaded lysine in Figure 1). There is an ATG site in the vector (42 bases 
upstream of the OXR1 sequence) that is a potential translational start site for OXR1. If used, 
it would generate an OXR1 protein that has an additional 13 amino acids (encoded by the 
vector) fused to the N-terminus of OXR1. However, removal of this putative start site (in 
pMV1248) did not affect the size of the OXR1 protein produced relative to that by encoded 
by pMV520 (as determined by SDS-PAGE; see section on C-terminal OXR1 deletions 
described below). This result strongly suggests that the ATG sequence within the vector is 
not the start site for OXR1translation in pMV520. Secondly, the vector-encoded start codon 
in pMV520 is preceded by an in-frame stop codon 15 base pairs upstream and does not have 
a correctly positioned ribosome binding site preceding it, making it an unlikely start site for 
translation. Finally, when a construct is made that places an ATG start site in front of codon 
200 of exon 7 (pMV1260), an OXR1 product of larger size (relative that produced by 
pMV520) is observed (data not shown). 
Figure 1 The human OXR1 gene. Top: The genomic structure of OXR1 consists of 16 
known exons located on chromosome 8q23. Exons, or portions of exons shown in black are 
present in an oxidation resistance active form of OXR1 previously described [24], whereas 
exons in white are known to be dispensable for this activity.  Exon 10 is found in a variant 
that begins with exon 10 and includes exons 12 through 15 [43].   Bottom:  The protein 
sequences encoded by OXR1 exons 7 through 16 are listed.  The starting points for the series 
of OXR1 N-terminal truncations were constructed by placing an ATG at the codon prior to 
position 203 (shaded lysine) of exon 7, using the methionine codon at position 225 (shaded) 
in exon 7, or by placing an ATG start codon in front of the codons encoding the first residues 
listed for exons 8 through 13 (except exon 10). The end points for the series of OXR1 C-
terminal truncations are denoted by the arrows.  Exon 10 is listed here, but was not found in 
pMV520; it is shown here for completeness 
These results strongly suggest that OXR1 made from pMV520 starts downstream of the 
lysine at codon position 200 of exon 7. Thus, the methionine encoded at position 225 of 
OXR1 exon 7 is designated as the first amino acid residue of “full length” OXR1 protein 
produced from pMV520 (see Figure 1). This full-length designation is only in respect to the 
region of OXR1 that is responsible for the anti-oxidant activity identified by the papillation 
assay in these experiments. Splice variants that carry exons not examined here (exons 1–6) 
may have additional functions, some of which may or may not be involved in oxidative 
repair. All exons listed in Figure 1, except the first 199 codons of exon 7 and exon 10, are 
found in the pMV520. Exon 10 is used as an alternative start codon of a splice variant that 
includes exons 10 and 12 through 16, which has no detectable oxidation antimutator activity 
(data not shown). 
OXR1 N-terminal deletions 
A series of plasmids containing N-terminal deletions of the OXR1 gene was transformed into 
strain MV4709 (mutM mutY) and tested for suppression of G→T transversions using the 
papillation assay described above. In these constructs, OXR1 is driven by Pmac, an artificial 
promoter designed to express genes under the control of IPTG (see Materials & Methods). 
The plasmids also encode the lacI repressor. As seen in Figure 2B, plasmids pMV1260 and 
pMV1263 that overexpress full-length OXR1 protein show a reduced plating efficiency upon 
induction, indicating they are toxic to E. coli in the presence of 1 mM IPTG. (In addition, 
pMV1260 also produces a larger protein that is generated by the transcription of sequences 
present, but not expressed, in pMV520; see legend to Figure 2A). A reduced plating 
efficiency was also observed for IPTG induction of cells containing pMV1266, which is 
missing all of exon 7, and produces an OXR1 N-terminal truncation starting with exon 8 
sequences. However, suppression of papillation is still observed among the colonies that do 
survive containing these three plasmids. On the contrary, OXR1 constructs starting with 
exons 9 or 12 (pMV1269 and pMV1275) are not toxic to E. coli upon IPTG induction and 
were unable to suppress the papillation phenotype. These results suggest that exon 8 is 
important for the mutagenic suppressor activity of OXR1, and/or the stability of the OXR1 
protein. 
Figure 2 (A) Diagram of N-terminal deletions of OXR1. In these assays, the full-length 
OXR1 construct is represented by both pMV1263, which starts with methionine 225 in exon 
7 (the expected start site of OXR1 in pMV520) and pMV1260, which encodes both this 
species and a slightly larger OXR1 species (by virtue of the presence of an initiating 
methionine start site inserted prior to codon 200 in exon 7). (B) Papillation assay for full-
length OXR1 species (pMV1260 and pMV1263) and three N-terminal deletions starting 
within exon 8 (pMV1266), exon 9 (pMV1269) and exon 12 (pMV1275). Plasmids were 
expressed in strain MV4709 (mutM mutY lacZ cc104) and plated on minimal lactose plates 
containing 100 μg/ml carbenicillin with and without 1 mM IPTG. Aliquots of 10-fold serial 
dilutions are plated beginning with undiluted cells on the left. No OXR1 controls containing 
pBR322 showed patterns that were identical to pMV1269 and p1275 (not shown). (C) 
Papillation assay for full-length OXR1 species (pMV1260 and pMV1263) and three N-
terminal deletions starting within exon 8 (pMV1266), exon 9 (pMV1269) and exon 12 
(pMV1275). Plasmids were expressed in strain MV4709 (mutM mutY lacZ cc104) containing 
pMS421 (LacI-producer) and plated on minimal lactose plates containing 100 μg/ml 
carbenicillin, 40 μg/ml streptomycin, 20 μg/ml spectinomycin and 1 mM IPTG. (D) SDS-
PAGE of extracts containing plasmids expressing OXR1 N-terminal deletions. Plasmid 
pMV1263 makes the full-length OXR1 species encoded by pMV520, while pMV1260 makes 
both this species and a slightly larger one that starts at position Lys-200 in exon 7. In 
addition, the arrows denote positions of observed protein bands for pMV1269 and pMV1272. 
(E) SDS-PAGE comparing full length OXR1 (pMV520) and OXR1 fragment starting at exon 
9 (pMV1269). Arrows denote positions of induced protein bands; full length OXR1 is present 
as a doublet (see text for details) 
As is apparent in Figure 2B, constructs pMV1260, pMV1263 and pMV1266 all show 
decreased colony forming ability relative to the non-suppressing plasmids in the presence of 
IPTG. This effect is observed despite the fact that these plasmids encode the lacI repressor. 
The ability of these plasmids to suppress the mutagenic phenotype of MV4709 may be due to 
the lower viability (or slower growth rate) due to overexpression of a toxic protein. To 
control the amount of OXR1 deletion fragments produced in vivo, strain MV4709 containing 
these plasmids were transformed with a compatible plasmid overexpressing the LacI 
repressor (pMS421), resulting in higher levels of LacI repressor being present (relative to 
cells expressing lacI from only the Oxr1-expressing plasmids). As shown in Figure 2C, this 
increase in LacI repressor protein expression in vivo had the effect of eliminating the toxicity 
effect of these plasmids when plated in the presence of 1 mM IPTG, without eliminating the 
suppressive effects of OXR1 expression on papillation (except pMV1263; discussed below). 
The papillation assay in this background shows that a construct expressing OXR1 starting at 
exon 8 (pMV1266) suppresses the mutagenic phenotype of MV4709 without causing 
toxicity. As before, constructs starting at exons 9, 11 or 12 did not exhibit any suppressor 
activity 
The lack of papillation suppression by the OXR1 fragment encoded by pMV1269, designated 
OXR1(9–16), might be due to differential expression of the OXR1 deletion mutant proteins. 
Thus, extracts of cells containing these constructs were run on SDS-PAGE. As seen in Figure 
2D, one observes a decrease in OXR1 fragment production upon loss of exon 8 (compare 
lanes 3 and 4), suggesting the importance of the protein domain encoded by exon 8 in OXR1 
stability in E. coli. While the decrease in protein production seen with OXR1(9–16) probably 
explains the loss of toxicity observed with pMV1269 in Figure 2B, we do not believe that this 
decrease in protein level can explain the inability of OXR1 (9–16) to suppress papillation. 
This conclusion is based on the observation that similar levels of protein are seen in extracts 
of cells expressing full length OXR1 from pMV520 (which suppresses papillation) and the 
OXR1(9–16) fragment from plasmid pMV1269 (which does not suppress papillation – see 
arrows in Figure 2E). Thus, enough OXR(9–16) fragment is present in cells containing 
pMV1269 that if it did contain OXR1’s oxidation resistance activity, it would suppress the 
mutagenic phenotype of MV4709 host cells. Plasmid pMV1272 produces an OXR1 fragment 
starting at exon 11 and encodes a stable protein but is unable to suppress papillation, while a 
construct encoding an OXR1 fragment starting at exon 12 (pMV1275) did not produce a 
stable protein (Figure 2D, lanes 5 & 6, respectively). Finally, a construct expressing only 
exons 13–16 also did not show suppression of papillation activity, although it did show a 
stable protein fragment when extracts were run on SDS-PAGE (data not shown). Overall, 
these results show that exons 9–16 are not required for the oxidation resistance activity 
exhibited by full length OXR1. This result was a little surprising, as this region of OXR1 
shows the highest homology among comparisons to other OXR1 variants [24] and contains a 
conserved protein domain found in a number of eukaryotic proteins with nuclear function - 
the TLDc domain [37]. 
One other interesting feature is apparent in the results shown in Figure 2C. Under these 
conditions of limited expression of these OXR1 constructs, the plasmid pMV1263 did not 
exhibit suppressor activity, even though a plasmid missing an additional 31 residues 
(pMV1266) did show suppressor activity. This result is not due to a mutation in pMV1263, as 
sequencing of the promoter and OXR1 region of this construct did not reveal any differences 
relative to the wild type sequences. Furthermore, this differential suppression is not due to 
different levels of expression of the OXR1 fragments in these constructs, as both pMV1263 
and pMV1266 show similar levels of protein expression on SDS-PAGE gels (see Figure 2D, 
compare lanes 2 and 3). One possibility for this observation is that the last 25 amino acid 
residues encoded by exon 7 may contain a control segment for OXR1 activity, which when 
exposed by removal of exon 7 residues 203–224, results in inhibition of the suppressor 
activity encoded within exon 8. Note however, that this inhibition can be relieved by further 
overexpression of this particular construct (when the LacI overproducer is absent - see Figure 
2B). Further biochemical and mutational analysis of OXR1 activity within this region will be 
needed to verify this hypothesis. In addition, this result demonstrates that overproduction of a 
foreign protein does not in itself induce suppression of the mutagenic phenotype of MV4709. 
C-terminal deletions of OXR1 
Carboxy-terminal deletions of OXR1 were constructed to identify what distal exons of OXR1 
are important for activity and/or stability of the protein. These plasmids are controlled by the 
IPTG-inducible Ptrc promoter; the OXR1 sequence starts at position 200 in exon 7 in all the 
constructs. As described previously, translation from these plasmids most likely initiates with 
the methionine at position 225 of exon 7. The C-terminal encoding endpoints in these 
plasmids are found at various points between exons 12 and 16 (see arrows in Figure 1). After 
transformation into MV4709 containing the LacI-producing plasmid pMS421, the ability of 
these constructs to suppress mutagenesis was assessed by the papillation assay. 
As can be seen in Figure 3B, all four of the OXR1 C-terminal deletions were capable of 
suppressing papillation when plated in the presence of 0.125 mM IPTG. At 1.0 mM IPTG, 
overexpression of these OXR1 fragments caused toxicity. Interestingly, overexpression of 
these OXR1 fragments with 1 mM IPTG prevented suppression when high amounts of cells 
were plated, but still showed suppression of papillation when single colonies were examined 
(see Figure 3B). This effect was not observed when toxic levels of the N-terminal fragments 
were plated (see Figure 2B). (The toxicity seen when the C-terminal deletions were plated 
with 1 mM IPTG in strain MV4709 containing pMV421, but not with the N-terminal 
deletions described above (Figure 2C), is likely the result of the higher transcriptional activity 
of the Ptrc promoter relative to Pmac.) Thus, removal of OXR1 exons 13–16 (including the 
TLDc domain) had no effect on the ability of these fragments to suppress papillation (and 
thus oxidative damage), consistent with the results from the N-terminal deletion constructs 
described above. 
Figure 3 (A) Diagram of C-terminal deletions of OXR1. (B) Papillation assays with 
plasmids expressing OXR1 C-terminal deletions in MV4709 containing LacI-producing 
plasmid pMS421. Dilutions and cell platings were as in Figure 2B using plates containing 
0.125 mM and 1.0 mM IPTG on minimal lactose plates containing 100 μg/ml carbenicillin, 
40 μg/ml streptomycin and 20 μg/ml spectinomycin. (C) SDS-PAGE of extracts containing 
plasmids expressing OXR1 C-terminal deletions 
Extracts of MV4709/pMS421 cells expressing these fragments were run on SDS-PAGE to 
examine the level of proteins produced. As seen in Figure 3C (lane 2), a doublet band is 
observed for the full length OXR1 expressed from pMV520. Given the close spacing of these 
bands, the difference in size between them is likely to be about 1–2 kDa. The doublet band of 
OXR1 is also observed in a second full-length OXR1 construct that promotes higher levels of 
protein (pMV1248 – see Figure 3C, lane 3) and with all four of the OXR1 C-terminal 
deletion constructs (see Figure 3C, lanes 4–7). Thus, the most likely explanations for the 
OXR1 doublet is either (1) a second restart site at the GTG site 13 codons downstream of the 
ATG start site, or (2) in vivo degradation of 10–20 amino acids from the N-terminus. A 
construct that initiates from a start codon placed at the beginning of exon 8 encodes a single 
discrete species (Figure 2D, lane 3). Thus, if the doublet is due to partial degradation, it is 
limited to sequences encoded within the last 31 residues of exon 7. 
Internal deletions of OXR1 fragment containing OXR1 exons 8–13 
Plasmid pMV1282 encodes OXR1 exons 8, 9, 11, 12 and 13 driven by the Pmac promoter (see 
Materials and Methods). A high level of expression of the OXR1 fragment was observed 
from extracts of IPTG-induced cells containing this plasmid (data no shown). Overexpression 
of this OXR1 fragment from this construct was toxic (similar to the N-terminal series of 
deletions described above). To down-regulate the expression of the OXR1 fragment encoded 
by pMV1282, rrnB T1 and T2 terminators were removed by digestion with SacI and XbaI, 
filling-in with T4 DNA polymerase and dNTPs, and religating. The resulting plasmid 
(pMV1293) showed lower amounts of the OXR1 fragment relative to pMV1282 as seen on 
SDS-PAGE (data not shown). It is presumed that removal of the terminator sequences from 
the plasmid destabilized the resulting transcript. Plasmid pMV1293 expresses exons 8, 9, 11, 
12 and thirty-nine out of the fifty-one residues encoded by exon 13. It suppresses the mutator 
phenotype of MV4709/pMS421 (mutM mutY) when single colonies are examined; see Figure 
4B. When the OXR1 fragment from pMV1293 is expressed in MV4709/pMS421, a protein 
band is observed on SDS-PAGE consistent with the expected size of the OXR1 fragment 
encoded by these exons (25.6 kDa; see Figure 4C, lane 2). 
Figure 4 (A) Diagram of internal-terminal deletions of OXR1 (8–13). (B) Papillation 
assays with plasmids expressing OXR1 internal deletions in MV4709 containing LacI-
producing plasmid pMS421. Dilutions and cell platings were as in Figure 2B using plates 
containing 1.0 mM IPTG on minimal lactose plates containing 100 μg/ml carbenicillin, 40 
μg/ml streptomycin and 20 μg/ml spectinomycin. (C) SDS-PAGE of extracts containing 
plasmids expressing OXR1 internal deletions 
A series of plasmids containing in-frame internal deletions of pMV1293 were constructed 
and tested for their ability to suppress the papillation of MV4709/pMS421. Plasmid 
pMV1294 contains an internal deletion that removes most of exons 8 and 9. This plasmid did 
not produce a stable band on SDS-PAGE, and not surprisingly, did not suppress papillation 
(Figure 4B & C). This result suggests that this region of the protein is important for stability 
of the OXR1 (8–13) fragment, as noted above for the N-terminal deletion plasmid pMV1269. 
Plasmid pMV1295, which is missing the latter half of exon 9, exons 11 and 12, did suppress 
papillation and showed a band on SDS-PAGE consistent with the size of the expected 
fragment (~15 kDa; see Figure 4C, lane 4). In fact, the suppression exhibited by pMV1295 
was more efficient than that seen with pMV1293, which contains exons 8–13 (see Figure 4B, 
compare rows 2 and 4). In this case, papillation suppression was noted when high numbers of 
cells were plated (see Figure 4B, row 4). The only intact exon in pMV1295 is exon 8, 
showing again that this domain encodes the active suppressor function. Finally, a plasmid 
that contains exons 8–12 but is missing all but the first 12 residues of exon 13 (pMV1296), 
still suppressed papillation within single colonies, but to a lesser extent than pMV1293 (an 
effect likely due to lower amounts of this protein fragment relative to the OXR1 (8–13); see 
Figure 4C, compare lanes 2 and 5, see arrow). The most likely explanation for this 
observation is that a stability determinant of this protein is present in exon 13 and that its 
presence in pMV1295 stabilizes exon 8, enhancing its activity. 
Internal deletions of full-length OXR1 (8–16) 
Given the above results suggesting that exon 8 encodes the anti-oxidant activity of OXR1, a 
Robson-Garnier analysis [38] of the protein secondary structural features of the protein 
fragment encoded by exon 8 was performed (Figure 5A). Highlighted in this analysis is a 
potential helix-turn-helix segment encoded by residues 9–36 (boxed in Figure 5A), and a 
second (smaller) helix-turn-helix segment encoded by residues 38–49. Understanding that 
protein secondary structural prediction programs are not definitive, we used these predictions 
as a guide to generate a second set of internal deletions of OXR1, this time starting with the 
full length construct (containing exons 8–16). Plasmids were constructed that removed each 
of these regions separately (pKM398 and pKM407) and together (pKM406), as well as 
deletions in the latter part of exons 8 and 9 (see Figure 6A). Papillation and SDS-PAGE 
analyses of these constructs are shown in Figure 6B and 6C, respectively. 
Figure 5 (A) Secondary structural prediction of the polypeptide encoded by OXR1 exon 
8 based on the method of Garnier et al [38]. Boxed region of protein sequence defines the 
putative larger helix-turn-helix region of the protein. (B) ClustelW alignment of the protein 
sequences encoded by OXR1 exon 8 and NCOA7 exon 9 
Figure 6 (A) Diagram of internal deletions of exons 8 and 9 within constructs expressing 
full length OXR1 proteins (exons 8–16). Bars represent regions of exon 8 that are missing 
in the OXR1 deletion mutants. (B) Papillation assay for control plasmid (pBR322), an OXR1 
encoded by exons 8–16 (pMV1266), and the five internal deletions of OXR1 diagrammed in 
part A. Plasmids were expressed in strain MV4709 (mutM mutY lacZ cc104) containing LacI-
producing plasmid pMS421. Dilutions and cell platings were as in Figure 2B using 0.125 mM 
and 1.0 mM IPTG on minimal lactose plates containing 100 μg/ml carbenicillin, 40 μg/ml 
streptomycin and 20 μg/ml spectinomycin. (C) SDS-PAGE comparing full length OXR1 
(pMV1266) and OXR1 deletion mutants described in part A. The expected sizes of the 
protein fragments from these plasmid are as follows: pMV1266 (38.2 kDa); pKM398 (35.2 
kDa); pKM406 (33.1 kDa); pKM407 (36.5 kDa) pKM394 (36.8 kDa); pKM361 (35.5 kDa) 
A plasmid (pKM406) that encodes a protein that is missing both predicted helix-turn-helix 
structural features failed to suppress papillation on plates containing either 0.1 or 1.0 mM 
IPTG (Figure 6B, row 4). This result is due to the lack of significant protein production seen 
with this construct (Figure 6C), again arguing for the presence of a major stability 
determinant encoded by exon 8. A plasmid (pKM407) that encodes an OXR1 protein that 
contains the first (larger) predicted helix-turn-helix encoded by exon 8, but not the second 
one, was fully capable of papillation suppression at 0.1 mM IPTG (see Figure 6B, row 5). 
The construct also exhibited inhibition of cell growth at higher concentrations of IPTG, as 
observed with the full length OXR1 protein. A plasmid construct (pKM398) missing the first 
predicted helix-turn-helix feature, but containing the second one, was also tested. This 
construct was not able to inhibit papillation at 0.1 mM IPTG, but did so in the presence of 
higher amounts of IPTG (See Figure 6B). SDS-PAGE analysis of extracts of these cells 
(Figure 6C) shows that this effect could largely be attributed to the differences in stable 
protein production from plasmids pKM398 and pKM407 (compare lanes 4 & 6 in Figure 6C), 
making it hard to assign the supression of mutagenesis function to principally one or the other 
region in exon 8. Nonetheless, these results show that either predicted helix-turn helix region 
of exon 8 is sufficient to prevent oxidative damage. In addition, the first predicted helix-turn-
helix region of exon 8 encodes the major stability determinant of the OXR1 protein. Finally, 
a plasmid construct encoding OXR1 deleted of the latter part of exon 8 and the beginning of 
exon 9 (pKM361), and a plasmid expressing OXR1 deleted of a predicted helix in exon 9 
(pKM394), both formed stable proteins that were fully capable of papillation suppression at 
0.1 mM IPTG (Figure 6B and C). These results are in agreement with those discussed above 
for N-terminal deletion mutants that exon 9 is not involved in oxidative damage protection. 
A summary of these experiments is shown in Table 1. It is evident that all the constructs that 
express a stable form of OXR1 containing exon 8 are fully (or partially) capable of 
suppressing the oxidative mutator effect exhibited by the tester strain, MV4709 (mutM mutY). 
All other deletions have neither an effect on toxicity (when overexpressed) nor the capability 
to suppress papillation. Thus, exon 8 encodes the peptide sequences required for the oxidative 
mutagenesis suppression activity of the human OXR1 protein. Finally, we note that the exon 
8-encoded protein sequence contains a cysteine residue at position 18, that might be a 
reactive residue involved in oxidative damage repair. We tested this prediction by altering 
Cys-18 of exon 8 to alanine in plasmid pMV1266. However, the C18A mutant was as 
capable as the wild type OXR1 sequence for suppression of papillation, ruling out a role for 
this cysteine residue in oxidative damage repair or prevention. 
Table 1 Papillation results from plasmids expressing OXR1 derivatives 
. Plasmid # Description Promoter; terminators Papillation 
suppression 
pMV520 Exon 7 (200) – Exon 16 (45) Ptrc + 
C-terminal deletions: regions present*   
pMV1248 exon 7 (200) – exon 16 (44) Ptrc + 
pMV1255 exon 7 (200) – exon 15 (20) Ptrc + 
pMV1256 exon 7 (200) – exon 13 (39) Ptrc + 
pMV1257 exon 7 (200) – exon 13 (15) Ptrc + 
pMV1258 exon 7 (200) – exon 12 (31) Ptrc + 
pMV1293 exon 8 (1) – exon 13 (39) Pmac + 
N-terminal deletions: regions present*   
pMV1260 exon 7 (200) – exon 16 (44) Pmac; rrnT1 + 
pMV1263 exon 7 (225) – exon 16 (44) Pmac; rrnT1 + 
pMV1266 exon 8 (1) – exon 16 (44) Pmac; rrnT1 + 
pMV1269 exon 9 (1) – exon 16 (44) Pmac; rrnT1 - 
pMV1272 exon 11 (1) – exon 16 (44) Pmac; rrnT1 - 
pMV1275 exon 12 (1) – exon 16 (44) Pmac; rrnT1 - 
pMV1278 exon 13 (1) – exon 16 (44) Pmac; rrnT1 - 
Internal deletions: regions deleted**   
pMV1294 Δ exon 8 (14) – exon 11 (11) Pmac - 
pMV1295 Δ exon 9 (42) – exon 13 (10) Pmac + 
pMV1296 Δ exon 13 (13–39) Pmac +/− 
pKM361 Δexon 8 (51) – exon 9 (16) Pmac; rrnT1 + 
pKM394 Δexon 9 (29–42) Pmac; rrnT1 + 
pKM398 Δexon 8 (9–36) Pmac; rrnT1 + 
pKM406 Δexon 8 (9–50) Pmac; rrnT1 - 
pKM407 Δexon 8 (37–50) Pmac; rrnT1 + 
Quantitative analysis of OXR1 mutation suppression 
The papillation assay is very sensitive for detection of the mutagenic suppression activity of 
OXR1. Nonetheless, we preformed a more quantitative analysis on some of the OXR1 
fragment-producing constructs described above. Lac
+
 reversion frequencies of MV6543 
(mutM mutY lacZcc104) were determined by growing cells overnight and plating on M9 
minimal plates containing lactose as the sole carbon source (as described in the Methods 
section). In the absence of OXR1, MV6543 generated over 350 Lac
+
 revertants per 10
8
 cells 
plated (see Figure 7A). Expression of an OXR1 fragment, starting with sequences encoded by 
exon 8 (pMV1266), fully suppressed Lac
+
 reversion frequencies of MV6543 by 99.4 %, 
down to levels exhibited by wild type E. coli (Figure 7A; [34]). Plasmid pM406, which 
encodes an OXR1 derivative that is largely deleted of exon 8, did not suppress the mutagenic 
activity of MV6543, consistent with the papillation assay. In large part, this result is likely 
due to the inability of this construct to produce a stable protein (see Figure 6C). Plasmid 
pKM398, deleted of exon 8 sequences encoding residues 9–36, also showed no suppression 
of mutagenic activity in the Lac
+
 reversion assay. This result differs from the papillation 
assay, where growth of cells containing pKM398 (only in the presence of 1 mM IPTG) did 
suppress papillation to a degree (see Figure 6B). These different results for pKM398 can be 
ascribed to either the greater sensitivity of the papillation assay in measuring mutagenesis, or 
to differences in the residual activity of this OXR1 deletion mutant when grown in liquid 
culture (in LB) versus M9 minimal plates. Plasmid pKM407, however, deleted of sequences 
encoding residues 37–50 of exon 8, inhibited mutagenesis by 97 % (close to the level 
exhibited by pMV1266) consistent with the results of the papillation assay described above. 
Figure 7 (A) Lac + reversion frequencies of MV6543 (MV4709 with pMS421) containing 
various OXR1 fragment-producing plasmids. Cells containing plasmids were grown 
overnight as described in the Methods section. All cultures contained 1 mM IPTG, except 
ones that contained pMV1266 and pKM407, which contained 0.1 mM IPTG (to prevent 
lethality that results from higher levels of expression of these OXR1 proteins). All cultures 
grew to saturation (2–4 x 109 cells/ml). The results are reported as the mean of 3–6 
determinations for each strain; error bars report the standard error. A t-test analysis of the 
values reported for pKM398 and pKM406 determined that there is no significant difference 
between the two frequencies reported for these plasmids. (B) Diagram of the OXR1 
fragment-producing plasmids used in the Lac  +  reversion assay 
Two other plasmids were also examined in the Lac
+
 reversion assay. Both pMV1258 
(encoding a C-terminal deletion of exons 13–16) and pMV1295 (expressing only exon 8 and 
part of exon 13), which both showed high levels of suppression using the paplliation assay, 
also showed inhibition of mutagenesis in the Lac
+
 reversion assay to 84 % and 69 % of the 
level exhibited by MV6543 containing the control plasmid. Again, the lack of full 
suppression with these plasmids using the Lac
+
 reversion assay can be attributed to the 
greater sensitivity of the papillation assay, or to differences in OXR1 activity of these 
mutants when grown in liquid culture versus solid media. Overall, however, the results of the 
papillation assays and the Lac  +  reversion frequencies are in good agreement; that is, that 
exon 8-encoded residues 9–36 play a critical role in the mutagenic suppression capability of 
the human OXR1 protein. 
Discussion 
These results show that OXR1 amino acids 9–36 of exon 8 is a key region responsible for the 
oxidative antimutator activity of OXR1. This region is also an important stability determinant 
of the OXR1 protein expression in E. coli. While it might be concluded that this region is 
simply required for stability of OXR1, with the repair function encoded by a different region 
of OXR1, this supposition is not supported by consideration of results from all the deletion 
mutants. For instance, the analyses of the C-terminal deletion mutants shown in Figure 3 
reveal that exons 13–16 are not required for the anti-oxidation activity exhibited by full 
length OXR1. This result was a little surprising, as this region of OXR1 shows the highest 
homology among comparisons to other OXR1 variants [24] and contains a conserved protein 
domain found in a number of eukaryotic proteins with nuclear function - the TLDc domain 
[37]. Sequences present in exon 12 can also be ruled out as important for OXR1 activity, as 
plasmid pMV1292 expresses a stable protein (which includes this region), but does not 
suppress papillation (Figure 2 C&D). Most revealing however, is the result for plasmid 
pMV1295, which contains exon 8 as the only intact exon of OXR1 and is completely capable 
of suppressing papillation (Figure 4). Taken together, the results reported here suggest that 
exon 8, especially the region encoding a large predicted helix-turn-helix region, is the key 
determinant for the oxidation resistance function of the OXR1 protein. 
The human gene NCOA7 encodes a protein that associates with the estrogen receptor, is 
targeted to the nucleus, and is highly homologous to OXR1 [24,39]. The gene is expressed in 
a variety of tissues, but is most highly expressed in neurons. It has been proposed that 
NCOA7, by binding to the estrogen receptor, might alleviate the oxidative damage that 
results from estradiol metabolism [34]. Other enzymes involved in the repair of DNA damage 
have also been identified that bind to the estrogen receptor [40-42] and may play a similar 
role in protecting DNA from oxidative damage. Durand et al. [34] showed that C-terminal 
fragments of NCOA7 containing the TLDc domain were capable of oxidative damage repair 
in E. coli. Of note, however, is that the fragment of NCOA7 used in that assay also contained 
most of exon 9, the exon homologous to OXR1 exon 8 examined in this report. An alignment 
of these two exons is shown in Figure 5B. The C-terminal fragment of NCOA7 that was 
competent for oxidative repair in E. coli started with the methionine at position 15 of exon 9. 
At this position, the C-terminal fragment of NCOA7 contains the regions most homologous 
to OXR1 exon 8, the exon described here as being critical for OXR1 oxidative damage 
suppression. Although not part of the TLDc domain (which in OXR1 starts near the end of 
sequence encoded in exon 12) a comparison of OXR1 sequences from a variety of organisms 
shows that exon 8 is highly conserved, especially among higher eukaryotes. 
OXR1 and its close homolog NCOA7 are produced in many different forms either as a result 
of alternative splicing, or alternative transcription start sites. Most of these isoforms include 
exon 8 of OXR1, or its counterpart (exon 9) of NCOA7, indicating that their antioxidant 
functions are key features of the gene products. However, there are several isoforms that 
include only the C-terminal TLDc domain that lack exon 8. The best characterized of these 
isoforms is the OXR1 C7C variant originally described by Fischer et al.. [43] and its human 
counterpart. This variant includes OXR1 exon 10, which is not found in other variants of 
OXR1. The human form of this variant of OXR1 lacks antioxidant activity, as no suppression 
of oxidative mutagenesis is seen when this protein is highly expressed in the E. coli mutM 
mutY strain (unpublished observations). This result eliminates the possibility that exon 10 can 
replace the oxidation resistance function of exon 8. These results suggest that in addition to 
the conserved oxidation resistance function, these highly conserved proteins may have 
additional functions that have not been characterized and that this hypothetical function is 
contained within the highly conserved C-terminal TLDc domain. 
Oliver et al. [32] have recently reported that loss of mouse OXR1 (mOXR1) resulted in the 
onset of an ataxia phenotype two weeks after birth in bel mice, followed by death within the 
first month of life. The authors found that the cerebellar granual cell layer (GCL) of these 
mice were sensitive to hydrogen peroxide more than normal controls, an effect that could be 
reversed by lentiviral expression of an OXR1 transgene. Notably, using a gene-trap construct, 
they found that in vivo expression of the C-terminal region of mOXR1 (mOXR1-C), which 
corresponds to exons 12–16 of hOXR1, was capable of reversing the neurological phenotype 
and early death of bel mouse mutant. In addition, they show that mOXR1-C expression could 
protect both wild-type and bel mutant GCL cells from hydrogen peroxide-induced apoptosis. 
On the contrary, we find that the C-terminal region of the hOXR1 was neither necessary or 
sufficient for suppression of oxidative damage in E. coli, and instead, that the function 
required for the antimutator phenotype resides in exon 8, which is present in both full-length 
and intermediate splice variants of hOXR1. 
Combining the results of both studies, a model emerges regarding the different functional 
characteristics of the mammalian OXR1 protein. The TLDc domain in the C-terminus of 
mOXR1 is clearly required for a key function of OXR1 that protects cells from oxidative 
damage, as shown by the study of Oliver et al. [32]. These authors go on to show that the 
mOXR1-C domain can interact with H2O2 via oxidation of a reactive cysteine (Cys753), 
suggesting that OXR1’s oxidative antimutator function may be the result of a direct 
interaction between the protein and reactive oxygen species. However, as the authors noted, 
the rate constant for this reaction was thousands of times lower relative to antioxidants that 
work in this manner (such as catalase and peroxiredoxins), leading them to suspect that the 
TLDc domain of mOXR1 has another type of function, or perhaps operates in a regulatory 
capacity. A regulatory role of OXR1 has been suggested by Jaramillo-Gutierrez et al. [26] 
who showed that silencing of OXR1 in mosquitoes resulted in lower levels of transcripts 
coding for enzymes such as catalase and glutathione peroxidase, proteins that act directly in 
detoxification of ROS. In this study, using our E. coli assay, we find that an oxidative 
antimutator function is not found in the hOXR1 C-terminal region, leading to the greater 
likelihood that this domain may instead have regulatory role, perhaps after an interaction with 
certain types of reactive oxygen species. Along these lines, the dispensability of the hOXR1 
C-terminal region in our E. coli assay is not unexpected if the TLDc domain’s principal role 
in mammalian cells is to regulate antioxidative operons, an effect not likely reproducible in E. 
coli. 
We favor a model of hOXR1 where an antioxidant activity is encoded by exon 8, with the C-
terminal domain conferring a regulatory region that responds to ROS. At least in E. coli, the 
proposed C-terminal regulatory region is not required for antioxidant function. Splice variants 
that include full length or intermediate species of hOXR1 may then reflect the need for both 
antioxidant activity and antioxidant-regulatory functions, whereas in tissues where only the 
short C-terminal region of hOXR1 is present may require only the regulatory feature of the 
OXR1 protein to protect from ROS. The study by Oliver et al. [32] showed that the shorter 
mOXR1-C form is present in the brain at low levels, though it is as highly expressed in the 
cerebellum as full length mOXR1. Such differences may reflect the need for regulatory 
capabilities of mOXR1 more so in the cerebellum than in the rest of the brain, where both an 
oxidative antimutator function and a regulatory region are required. As mentioned in the 
Introduction, these authors also reported an upregulation of intermediate forms of OXR1 in 
ALS human biopsy samples, as well as in SOD1 mutant mice (a mouse model of ALS). The 
intermediate forms of OXR1 contain the upstream oxidative antimutator function we have 
identified here in exon 8 and may reflect the need for this activity as a protective function in 
ALS patients. It would be interesting to know if mutations in the hOXR1 gene also play a 
role in sporadic cases of ALS. 
What does OXR1 the exon 8-encoding function do? The region of exon 8 required for 
oxidation resistance shares homology only with other members of the OXR family of 
proteins suggesting they have a unique function not shared with other proteins that contribute 
to oxidative stress resistance. However, it has been observed that OXR1 can suppress 
mutagenesis in bacteria, indicating it does not require additional human proteins for function 
and can suppress mutagenesis resulting from mutations in genes inactivating several different 
types of oxidative lesions [24]. These results make it more likely that OXR1 exon 8-encoded 
region prevents rather than repairs oxidative damage, since oxidative damage repair enzymes 
typically recognize only a single, or a set of structurally similar lesions. Such a role for OXR1 
as an antioxidant protein is further supported by studies of oxr1 deletion mutants of yeast, 
which exhibit elevated levels or ROS, suggesting its function is to reduce ROS levels (Fenton 
and Volkert, unpublished results). 
Conclusion 
The human OXR1 gene exon 8 encodes a function required for the suppression of oxidative 
damage.  This oxidative resistance function is distinct from the highly conserved TLDc 
domain found in the C-terminal region of OXR1.  A model is proposed that OXR1 consist of 
two separable functions involved in oxidative resistance: a C-terminal domain that has a 
regulatory role in inducing oxidative resistance functions in response to oxidative damage, 
and an internal region of the protein encoded by exon 8 that possesses a antimutator 
“protective” function against reactive oxygen species. 
 
Methods 
Plasmid constructions 
Plasmid pMV520 has been described [24]. C-terminal deletion mutants of OXR1 were 
generated by cloning PCR-generated fragments of OXR1 into the EcoR1 and XmaI sites of 
expression vector pTrc99a. In these plasmids, OXR1 fragments are expressed from the Ptrc 
promoter. The endpoints of the OXR1 deletions are indicated by the arrows in Figure 1. 
Plasmids containing N-terminal deletions of OXR1 were generated by cloning PCR-
generated fragments of OXR1 into the NdeI and SacI backbone of pTP905 (A. Poteete, 
unpublished). In these constructs, OXR1 fragments are expressed from the IPTG-inducible 
Pmac promoter (P moderate lacUV5-like) [44]. The Pmac promoter sequence 
(TTTACATTGTGAGCGGATAACAATATAAT) contains a lac operator (italicized) between 
the −35 and −10 regions (underlined). These OXR1 N-terminal deletion vectors also contain 
an rrnT1 terminator downstream of the gene fragments, which confers greater stability to 
transcripts resulting in higher expression levels (unpublished observations). Two of these 
vectors (pMV1260 and pMV1263) start within the latter part of exon 7; the other plasmids in 
this series were constructed by adding a start codon in front of the first codon of exons 8, 9, 
11, 12 and 13, respectively. 
A plasmid pMV1293 was constructed that encoded an OXR1 fragment starting with exon 8 
and ending at residue 39 of exon 13. A PCR product (using a derivative of pMV520 as a 
template) was cloned into the NdeI-XbaI backbone of pMV1266, resulting in removal of the 
rrn T1 terminator. A series of internal (in-frame) deletions of pMV1293 were constructed by 
digestion of the plasmid with restriction enzymes and religation of the resulting backbone. 
Plasmids pMV1294, pMV1295 and pMV1296 were generated by digestion of pMV1293 with 
ClaI, MfeI and NcoI, respectively; the ClaI digestion was filled-in by T4 polymerase and 
dNTPs. The backbone (ori-containing) fragments were religated and transformed into 
competent E. coli cells overexpressing LacI (W3110 lacI
q
). The resulting plasmids contain in-
frame deletions of one or more of the OXR1 exons present in pMV1293; the residues absent 
in the OXR1 proteins encoded by these plasmids (relative to pMV1293) are listed in Table 1. 
Plasmid dilutions of pMV520 were used as a template for all PCR reactions. 
A second set of internal deletions within a full length OXR1 protein (defined here as the 
protein encoded by the exons listed in Table 1, with the exceptions of exons 7 and 10) was 
generated by λ Red recombineering [45,46]. Cassettes encoding a kanamycin-resistant 
determinant flanked by NotI sites (generated by PCR) were recombined into pMV1266 
resulting in various deletions of exons 8 and/or 9. An extra G nucleotide was included in one 
of the primers, so that following digestion of the modified pMV1266 plasmids with NotI and 
religation of the linearized plasmid, regions of OXR1 containing exon 8 and/or 9 were 
replaced with GCGGCCGCG. The resulting plasmids thus encoded in-frame deletions of 
OXR1, where the deleted regions of the OXR1 protein were replaced with 3 alanines. A 
summary of all the plasmids constructed for this study appears in Table 1. All plasmids 
modifications constructed in this study were verified by sequencing. Primers sequences used 
to generate the plasmid constructs are available upon request. 
Mutagenesis assays 
Full-length OXR1 protein and various truncations/mutations of OXR1 were expressed in 
strain MV4709 (mutM::Tn19 mutY::cat), which also carries the mutant lacZ cc104 allele 
[47]. This lacZ allele reverts to wild type by a GC to TA transversion, a common mutation 
known to occur during oxidative stress due to the high levels of 8-oxoG formation. Thus, one 
can follow the spontaneous oxidative damage occurring in this strain by the presence of blue 
papillae in single white colonies on plates containing Xgal and IPTG [47]. In order to 
moderate expression of OXR1 and mutant derivatives, host cells also contained the 
compatible plasmid pMS421 (a pGB2 derivative) that overexpresses the LacI repressor. Fresh 
cultures of MV4709 (mutM mutY) containing pMS421 (MV6543) and plasmids expressing 
wild type and various deletions of OXR1 were grown from overnight stocks to 2 x 10
8
 
cells/ml in LB media containing 100 μg/ml ampicillin, 40 μg/ml spectinomycin and 20 μg/ml 
streptomycin. Dilutions of the cultures were spot titered on minimal plates containing 0.2 % 
glucose, 1X A salts, 1 mM MgSO4, 0.5 mg/ml phenyl-β-D-galactopyranosie (P-Gal), 50 
μg/ml carbenicillin, 40 μg/ml X-gal and various concentrations of IPTG (see figure legends). 
Mutagenesis was observed by the high density of blue papillae present in single white 
Lac  +  colonies; suppression of papillation is indicative of OXR1 activity. 
The Lac
+
 reversion assay was performed essentially as described by Poteete [48], with some 
modifications. Small colonies of MV6543 cells (MV4709 with pMS421-Strep
R
-Spec
R
) 
containing various OXR1 fragment-producing plasmids (Amp
R
), were picked from LB plates 
containing ampicillin (100 μg/ml), spectinomycin (20 μg/ml), streptomycin (10 μg/ml), and 
resuspended in LB containing these same concentrations of drugs, and in addition, either 0.1 
mM or 1 mM IPTG (see legend to Figure 7). Between 3–6 colonies were picked for each 
strain containing an OXR1 fragment-producing plasmid. The cultures were grown overnight 
at 37
o
 C with aeration. Cells were collected by centrifugation and resuspended in 1 volume of 
1x M9 salts. Undiluted and diluted samples of cells (between 10
7
 and 10
8
 total) were plated 
on M9 minimal lactose plates to determine the number of Lac  +  revertants, and on LB 
plates to determine the total number of cells plated. M9 minimal plates contained 0.2 % 
lactose and were supplemented with thiamine at 5 μg/ml. Lac  +  reversion frequencies are 
reported as the number of Lac  +  revertants per 108 cells plated. To reduce background 
growth on the minimal lactose plates, 10
9
 scavenger cells, TP889 (ΔlacZ::cat) [48] were 
plated along with various amounts of the test cultures. The scavenger cells cannot revert to 
Lac+, but deplete the plates of trace energy sources preventing late-arising colonies from 
appearing, and in turn, lead to more accurate frequencies of Lac  +  reversion. The 
scavenger cells were prepared by growing a 50 ml culture of TP889 in LB overnight, 
collecting cells by centrifugation, washing once with cold 1x M9 salts and resuspending in 5 
ml cold 1x M9 salts; a total of 100 μl of scavenger cells were plated with each of the test 
strains on M9 minimal lactose plates. 
OXR1 Fragment production in vivo 
SDS-polyacrylamide gels were used to assess the presence of stable OXR1 protein fragments 
containing either deletions or site-specific mutations. Cultures (5 ml) were grown to 2 x 10
8
 
cells/ml in LB containing 100 μg/ml ampicillin, 40 μg/ml spectinomycin and 20 μg/ml 
streptomycin. IPTG was added to 1 mM concentration and cells were aerated by rolling for 
2.5 hours. The cultures were then collected by centrifugation and resuspended in 100 μl of in 
50 mM Tris–HCl, 100 mM NaCl, 1 mM EDTA, 10 % glycerol. Cells suspensions were 
diluted with an equal volume of H20 and then mixed with an equal amount of 2x SDS buffer. 
Samples were boiled for 3 minutes, run overnight at 50 volts on 10 % polyacrylamide gels 
using the Tricine system [49] or 12 % polyacrylamide using Tris buffers as previously 
described [50]. Gels were stained with Coomassie Blue. All the protein bands identified in 
this study as OXR1 full-length protein or proteins fragments were dependent upon the 
addition of IPTG. Cells not grown in the presence of IPTG showed the same pattern as the 
pBR322 control. A plasmid derivative of pMV1266 that had a frameshift mutation in the 
OXR1 gene resulted in the same pattern on these SDS-PAGE gels as pBR322-containing 
cells. 
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